<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938090</url>
  </required_header>
  <id_info>
    <org_study_id>012604</org_study_id>
    <nct_id>NCT03938090</nct_id>
  </id_info>
  <brief_title>Optimised MultiSite Pacing Vector Study</brief_title>
  <official_title>Multimodality Assessment of Acute and Long Term Response to Optimised MultiSite Pacing Cardiac Resynchronisation (MSP CRT) Devices Compared to Biventricular (BiV) CRT, in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Barts &amp; The London NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to evaluate the clinical benefits of an&#xD;
      MultiSite pacing (MSP) with patient specific left ventricular vector optimization in patients&#xD;
      receiving cardiac resynchronization therapy (CRT) after 6 months of therapy.&#xD;
&#xD;
      This clinical investigation is a single-center, prospective, two-arm, randomized 1:1,&#xD;
      crossover study designed to evaluate the effectiveness of Optimized MSP CRT compared to&#xD;
      conventional bi-ventricular pacing.&#xD;
&#xD;
      Data will be collected at enrolment, CRT implant procedure, hospital pre-discharge, one,&#xD;
      three and six months post implant. Enrolment data collection will include demographics,&#xD;
      cardiovascular history, medication, echocardiography measurements, heart failure quality of&#xD;
      life questionnaire and six minute walk test distance.&#xD;
&#xD;
      CRT implant procedure data collection will include implanted system information, lead&#xD;
      location and conduction times. The electrical conduction recording procedure will include&#xD;
      surface ECG and device electrogram (EGM) recordings during various MSP vector pacing&#xD;
      configurations at the time of CRT device implant.&#xD;
&#xD;
      Patients will also undergo simultaneous invasive pressure measurements using a left&#xD;
      ventricular pressure wire to allow haemodynamic measurements (dP/dtmax) during various MSP&#xD;
      vector pacing configurations.&#xD;
&#xD;
      Optimal MSP programming settings will be determined by the narrowest QRS duration recorded by&#xD;
      12 lead ECG and the greatest change in dP/dtmax by pressure wires study.&#xD;
&#xD;
      In a subgroup of patients (approximately 25 patients), non-invasive electrical activation&#xD;
      data will be collected with electrocardiographic imaging (ECGi) within 45 days of the implant&#xD;
      procedure.&#xD;
&#xD;
      Patients will then be randomized 1:1 to receive either standard biventricular pacing or&#xD;
      Optimized MSP at their one-month follow-up (± 15 days) visit.&#xD;
&#xD;
      At the 3 months (± 15 days) post randomization follow up visit, data collection will include&#xD;
      surface ECG, EGMs, echocardiographic parameters and quality of life questionnaire. The&#xD;
      patients will then undergo cross-over to the alternate randomization group with programming&#xD;
      adjusted accordingly.&#xD;
&#xD;
      At the final, 6 months (± 15 days) post randomization follow-up visit, data collection will&#xD;
      include surface ECG, EGMs, echocardiographic parameters and quality of life questionnaire.&#xD;
      This will mark the completion of the study for each patient.&#xD;
&#xD;
      The expected duration of enrolment is 18 months. The total duration of the clinical&#xD;
      investigation is expected to be 25 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">July 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-center, prospective, two-arm, randomized 1:1, crossover study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Echocardiographic clinical response</measure>
    <time_frame>3 and 6 months post randomization</time_frame>
    <description>Response to optimised MSP CRT compared to BiV CRT defined by LV systolic volume reduction of greater than 15% (indicative of &quot;reverse remodelling&quot;) at completion of follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute changes in surface ECG QRS duration and morphology</measure>
    <time_frame>Acute change in QRS duration with pacing compared to intrinsic QRS duration, measured during pacing programming protcol at device implant</time_frame>
    <description>QRS duration changes with CRT programming optimisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute change in LV dP/dtmax</measure>
    <time_frame>Acute change in LV dP/dtmax with pacing compared to intrinsic rhythm, measured during pacing programming protcol at device implant</time_frame>
    <description>Changes in LV contractility as assessed by pressure wire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity by 6MWT distance</measure>
    <time_frame>Pre-implant, 3 and 6 months post randomization</time_frame>
    <description>6 minute walk test distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NYHA functional class</measure>
    <time_frame>Pre-implant, 3 and 6 months post randomization</time_frame>
    <description>New York Heart Association Functional class</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sub-group outcome: assessment of LV activation timings with ECGi</measure>
    <time_frame>1 month post implant</time_frame>
    <description>Electrocardiographic imaging</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Heart Failure</condition>
  <condition>Left Bundle-Branch Block</condition>
  <condition>Systolic Dysfunction</condition>
  <arm_group>
    <arm_group_label>Standard biventricular pacing</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cardiac resynchronization therapy (CRT) devices will be programmed as per standard biventricular pacing settings</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimised MultiSite Pacing (MSP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cardiac resynchronization therapy (CRT) devices will be programmed as per optimal MSP programming settings; determined by greatest change in dP/dtmax and narrowest QRS duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimised MultiSite Pacing</intervention_name>
    <description>The intervention includes using optimal programming settings with MultiSite pacing configurations via the patient's CRT device. The device in use is the same for each arm, the only changes are the programming settings.</description>
    <arm_group_label>Optimised MultiSite Pacing (MSP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard biventricular pacing</intervention_name>
    <description>Conventional programming settings using biventricular pacing will be used</description>
    <arm_group_label>Standard biventricular pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic Heart Failure (NYHA class I-IV) with QRS duration of 150ms or more with&#xD;
             left bundle branch block and LVEF of 35% or less despite optimal medical therapy.&#xD;
&#xD;
          -  Patients above 18 years of age&#xD;
&#xD;
          -  Able to provide informed consent and willing to comply with study requirements&#xD;
&#xD;
          -  Intrinsic QRS duration ≥ 150 ms&#xD;
&#xD;
          -  Sinus (or atrial paced) rhythm with intact AV conduction (PR interval ≤250 ms)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Resting heart rate &gt; 100 bpm&#xD;
&#xD;
          -  High degree AV Block (2nd or 3rd degree AV block)&#xD;
&#xD;
          -  Documented persistent atrial arrhythmia at the moment of enrolment or patients not&#xD;
             likely to remain in sinus (or atrial paced) rhythm for the duration of the study&#xD;
&#xD;
          -  Patients scheduled for AV node ablation to treat atrial arrhythmias&#xD;
&#xD;
          -  Recent (&lt; 3 months) myocardial infarction, catheter ablation, electrolyte imbalance,&#xD;
             or any condition within the last 90 days that would contraindicate CRT programming&#xD;
             changes in the opinion of the investigator&#xD;
&#xD;
          -  Women who are pregnant or plan to become pregnant during the study course&#xD;
&#xD;
          -  Known left ventricular thrombus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony WC Chow, MBBS BSc MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Chief Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter H Waddingham, MBBS BSc</last_name>
    <phone>02037658635</phone>
    <email>p.waddingham@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victoria Baker, BA</last_name>
    <phone>02037658635</phone>
    <email>victoria.baker@bartshealth.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Bartholomew's Hospital, Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Peter H Waddingham, MBBS BSc</last_name>
      <phone>02037658635</phone>
      <email>p.waddingham@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Baker, BA</last_name>
      <phone>02037658635</phone>
      <email>victoria.baker@bartshealth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Peter H Waddingham, MBBS BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony WC Chow, MBBS BSc MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Resynchronization Therapy</keyword>
  <keyword>MultiSite Pacing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Bundle-Branch Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No participant data will be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

